我們已在上線！進一步了解

ARAV

Aravive, Inc. Common Stock

ARAV

市值 US$295萬

已下市

ARAV已於2024年1月26日下市。

返回排名列表

關於： Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

員工： 23

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 0%

負面 0%

Why Is Aravive (ARAV) Stock Down 52% Today?

Aravive (NASDAQ: ARAV ) stock is taking a beating on Thursday as the clinical-stage biopharmaceutical company prepares for its shares to be delisted from the Nasdaq Exchange. A press release from Aravive reveals that the company is voluntarily delisting shares of its common stock.

Proactive Investors

Aravive stock slumps on Nasdaq delisting plan, dissolution

Aravive Inc's shares fell over 58% in Thursday premarket trading after it announced plans to voluntarily delist its common stock on Nasdaq as it prepares to dissolve the company. In a statement, the late clinical-stage oncology company noted that it had already failed to meet the minimum listing requirements of the exchange, including the minimum market value and minimum bid price requirements.

Aravive, Inc. to Delist from The Nasdaq Stock Market

HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market (“Nasdaq”) and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and suspend its public reporting obligations.

Aravive, Inc. to Delist from The Nasdaq Stock Market

查看新聞排名

價格圖表採用Lightweight Charts™實作